Ocugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion. The company expects top-line data from its OCU400 retinitis pigmentosa program in the first quarter of 2027, followed by a […]